Literature DB >> 8641437

Wild type but not deltaF508 CFTR inhibits Na+ conductance when coexpressed in Xenopus oocytes.

M Mall1, A Hipper, R Greger, K Kunzelmann.   

Abstract

Airway epithelial cells bearing mutations of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) possess an increased Na+ conductance along with their well described defect of cAMP dependent Cl- conductance. Currently it is not clear, how this occurs, and whether it is due to a CFTR control of epithelial Na+ conductances which might be defective in CF patients. In the present study, we have tried to identify possible interactions between both CFTR and the epithelial Na+ conductance by overexpressing respective cRNAs in Xenopus oocytes. The expression of all three (alpha, beta, gamma) subunits of the rat epithelial Na+ channel (rENaC) and wild type (wt) CFTR resulted in the expected amiloride sensitive Na+ and IBMX (1 mmol/l) activated Cl- currents, respectively. The amiloride sensitive Na+ conductance was, however, inhibited when the wt-CFTR Cl- conductance was activated by phosphodiesterase inhibition (IBMX). In contrast, IBMX had no such effect in deltaF508 and Na+ channels coexpressing oocytes. These results suggest that wt-CFTR, but not deltaF508-CFTR, is a cAMP dependent downregulator of epithelial Na+ channels. This may explain the higher Na+ conductance observed in airway epithelial cells of CF patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8641437     DOI: 10.1016/0014-5793(96)00079-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  30 in total

Review 1.  Mucus clearance as a primary innate defense mechanism for mammalian airways.

Authors:  Michael R Knowles; Richard C Boucher
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

2.  The first-nucleotide binding domain of the cystic-fibrosis transmembrane conductance regulator is important for inhibition of the epithelial Na+ channel.

Authors:  R Schreiber; A Hopf; M Mall; R Greger; K Kunzelmann
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

Review 3.  The membrane transporters regulating epithelial NaCl secretion.

Authors:  R Greger
Journal:  Pflugers Arch       Date:  1996-08       Impact factor: 3.657

4.  Liddle's syndrome mutations disrupt cAMP-mediated translocation of the epithelial Na(+) channel to the cell surface.

Authors:  P M Snyder
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

5.  Gating of amiloride-sensitive Na(+) channels: subunit-subunit interactions and inhibition by the cystic fibrosis transmembrane conductance regulator.

Authors:  B K Berdiev; V G Shlyonsky; K H Karlson; B A Stanton; I I Ismailov
Journal:  Biophys J       Date:  2000-04       Impact factor: 4.033

Review 6.  Novel molecular approaches to cystic fibrosis gene therapy.

Authors:  Tim W R Lee; David A Matthews; G Eric Blair
Journal:  Biochem J       Date:  2005-04-01       Impact factor: 3.857

Review 7.  Targeted therapy for cystic fibrosis: cystic fibrosis transmembrane conductance regulator mutation-specific pharmacologic strategies.

Authors:  Ronald C Rubenstein
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

8.  CFTR fails to inhibit the epithelial sodium channel ENaC expressed in Xenopus laevis oocytes.

Authors:  G Nagel; P Barbry; H Chabot; E Brochiero; K Hartung; R Grygorczyk
Journal:  J Physiol       Date:  2005-03-03       Impact factor: 5.182

9.  The cystic fibrosis transmembrane conductance regulator (CFTR) inhibits ENaC through an increase in the intracellular Cl- concentration.

Authors:  J König; R Schreiber; T Voelcker; M Mall; K Kunzelmann
Journal:  EMBO Rep       Date:  2001-10-17       Impact factor: 8.807

10.  Development of chronic bronchitis and emphysema in beta-epithelial Na+ channel-overexpressing mice.

Authors:  Marcus A Mall; Jack R Harkema; Joanna B Trojanek; Diana Treis; Alessandra Livraghi; Susanne Schubert; Zhe Zhou; Silvia M Kreda; Stephen L Tilley; Elizabeth J Hudson; Wanda K O'Neal; Richard C Boucher
Journal:  Am J Respir Crit Care Med       Date:  2007-12-13       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.